News & Events
Published On: 10/1/2020
TARGET-DERM Real-World Study Success Leads To Global Site Expansion And New Dermatologic Conditions
DURHAM, N.C., Oct. 1, 2020 /PRNewswire/ -- Target RWE, an innovative health evidence solutions company that generates and analyzes real-world evidence (RWE), announced the expansion of its active longitudinal dermatology registry, TARGET-DERM (NCT03661866), into Canada and Europe. Launched in 2019, the study has enrolled more than 1,000 patients with Atopic Dermatitis (AD) across 42 academic and community sites throughout the United States.
Target RWE also announced that the TARGET-DERM study will expand data collection to capture real-world data on patients with hidradenitis suppurativa (painful boil-like lesions under the skin) and alopecia areata (autoimmune-related hair loss).
"It is exciting to see the expansion of TARGET-DERM beyond the U.S. into Canada and Europe. The uniqueness of the registry and the speed of its growth in the U.S. has been very impressive, and the extension internationally will add great value to the project," said TARGET-DERM Steering Committee Member, Robert Bissonnette, MD, Chief Executive Officer and Medical Director at Innovaderm Research, Inc. located in Montreal, QC, Canada.
"Building on the success of our AD enrollment and strong partner support, we are excited to expand TARGET-DERM globally to Canada and Europe by the end of 2020," said Neal Bibeau, CEO, Target RWE. "We are also pleased to begin including patients who live with alopecia areata and hidradenitis suppurativa, two dermatological conditions with major quality-of-life implications, in the hopes that our data analysis will uncover meaningful findings for these patients."
TARGET-DERM is an observational study following adult and pediatric patients with immune-mediated inflammatory skin conditions. Once enrolled, TARGET-DERM collects three years of retrospective data and five years of prospective data on patients. The registry could eventually include up to 15,000 patients and may expand to include vitiligo (loss of skin pigment) in the future. The TARGET-DERM real-world data collection includes extensive patient-reported outcome measures and biospecimen samples (whole blood, saliva, serum, and tape strips) on consented patients.
About Target RWE
Target RWE is a leading health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners. Specifically designed to address the complexities of the natural history of disease, the drug development process and treatments in real-world settings, Target RWE builds regulatory-grade clinical data sets and applies state of the science epidemiologic methods to produce RWE about patients with specific conditions, symptoms, and therapies used in usual clinical practice.
Target RWE's regulatory-grade data sets and evidence, modern epidemiological methods, and sound scientific principles rendered as software can be utilized to better health outcomes, inform patient health guidelines, and improve overall quality of care. For more information, visit www.targetrwe.com.
984.234.0268 ext 205
10/11/2021Target RWE Inflammatory Bowel Disease Research Presented at UEG Week 2021
09/13/2021Update from Paris NASH 2021: New Target RWE Nonalcoholic Steatohepatitis (NASH) Data Presented at This Year’s Meeting
07/01/2021Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and Sciences
06/29/2021Liver International Publishes Hepatocellular Carcinoma RWE Review
06/22/2021Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger Patients